Breaking News

Celgene Names New CEO

January 11, 2016

Alles takes over for Hugin, who’ll serve as executive chairman

Celgene Corp. has made organizational changes, effective March 1, 2016. Chairman and chief executive officer Bob Hugin will now serve as executive chairman and will continue to lead the board of directors and the strategic direction of the company. Mark Alles has been promoted to chief executive officer, and Jacqualyn Fouse, Ph.D., will be promoted to president and chief operating officer. Also, Scott Smith, president Immunology & Inflammation, will assume an expanded leadership role.
"I am excited for the opportunity to continue to significantly impact the lives of patients through advancing key strategic initiatives," said Mr. Hugin. "The elevation of exceptional leaders like Mark, Jackie and Scott will strengthen our organization and energize our operations allowing us to more fully realize our incredible potential, both benefiting Celgene and the patients that we serve."
"Bob Hugin is responsible for leading the transformation of Celgene into the global biopharmaceutical company that it is today," said Michael D. Casey, Celgene's lead independent director. "As CEO, Bob has delivered exceptional results and we are incredibly grateful that Bob will continue to lead the strategic direction of Celgene. In addition to being involved in key business matters, as executive chairman, Bob will increase his focus on the development of Celgene's next generation of leaders, his advocacy work to improve patient access and outcomes and on identifying the next wave of novel therapies for Celgene investment."
Mr. Alles is a 30-year industry veteran and has been with Celgene since 2004, most recently serving as president and chief operating officer, where he integrated corporate operational functions to support Celgene’s global commercial franchises. Prior to that he led Celgene's Hematology & Oncology franchise, including the global launches of REVLIMID and POMALYST and the acquisitions and integrations of Pharmion (VIDAZA) and Abraxis BioSciences (ABRAXANE).
Ms. Fouse joined Celgene in 2010 as chief financial officer and later became president of Celgene's Hematology & Oncology franchise. In her new role, she will focus on operational excellence, and driving exceptional performance across Celgene's franchises and functions.
Mr. Smith has been appointed to chair Celgene's Global Management Committee and will be responsible for the coordination of its operational and strategic imperatives. He joined the company in 2008 and will continue to be responsible for building and leading Celgene's I&I franchise.
"Mark is an extraordinary leader, whose knowledge of our business and commitment to patients have propelled the organization to incredible success," said Mr. Hugin. "Jackie's strong leadership and strategic capabilities set the standard for our organization. Scott is responsible for building our I&I franchise and has consistently delivered exceptional results. Mark's, Jackie's and Scott's wealth of industry and company experience, judgment and strategic vision are invaluable as we continue to lead the Company into the future."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks